Session Information
Session Type: Abstract Submissions (ACR)
Background/Purpose: The RCR provides ACR members with an infrastructure for quality reporting related to rheumatoid arthritis, gout, osteoarthritis, osteoporosis, and drug safety. Currently in its fourth year of operation, the RCR contains data on over 32,000 patients.
Here we report the uptake of the RCR by U.S. rheumatologists and performance on quality measures regarding functional status, disease modifying drug (DMARD) use, tuberculosis screening, prognosis, and disease activity assessment for RA patients in 2011 and 2012.
Methods: Data derive from retrospective medical records abstractions performed by providers and/or designated practice staff for a sample of patients seen by rheumatologists. Reporters submit data on quality measures via a secure, web-based registry system. Patients included in the denominator of all quality measures are >18 years of age with a diagnosis of RA who are receiving treatment by the reporting rheumatology provider. Additional details of each measure are listed in Table 1. We report the mean performance on each quality measure, defined as percentage of eligible patients receiving recommended care.
Results: Table 1 summarizes performance on RA measures reported through the RCR. From January 1, 2012 to December 31, 2012, 301 rheumatology providers in 138 practices submitted data on 9154 encounters with RA patients. Comparative data are provided for the previous reporting period. These data summarize 8096 encounters with RA patients submitted by 257 rheumatology providers in 143 practices from January 1, 2011 – December 31, 2011. Reporting providers practice in sites ranging from solo offices to large academic medical centers.
Table 1. Performance on RA Measures Assessed through the RCR
|
|
CY2011 |
CY2012 |
||
|
|
Patients (N) |
QM Performance Rate |
Patients (N) |
QM Performance Rate |
|
Disease activity assessed at least once within 12 months, using a standardized descriptive or numeric scale or composite index, and classified as low, moderate or high |
8075 |
43.3% |
6485 |
54.4% |
|
Functional status assessment performed at least once within 12 months, and documented using a standardized descriptive or numeric scale, standardized questionnaire, or notation of assessment of the impact of RA on patient activities of daily living |
8077 |
70.5% |
6485 |
86.6% |
|
Patient prescribed, dispensed, or administered at least one ambulatory prescription for a DMARD within 12 months |
7808 |
97.9% |
6485 |
86.6% |
|
Documentation of TB screening performed and results interpreted within 6 months prior to receiving first course DMARD |
1650 |
73.6% |
1048 |
92.9% |
|
Assessment and classification of disease prognosis at least once within 12 months |
7771 |
49.5% |
6441 |
73.4% |
Conclusion:
Performance rates increased on four out of five measures from CY2011 to CY2012. Based on preliminary results, the ACR plans to complete in-depth analyses of both measure and population performance.
Disclosure:
J. Yazdany,
None;
S. Kazi,
None;
R. Myslinski,
None;
M. Francisco,
None.
« Back to 2013 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/uptake-of-the-american-college-of-rheumatologys-rheumatology-clinical-registry-quality-measure-summary-data/